Back to Stakeholders

Hospitals Independent Academic Research Groups

NYU Langone Health

United States

9 Trials

Home to the NYU Langone Center for Psychedelic Medicine, one of the world's leading academic institutions in psychedelic research. Has conducted landmark psilocybin trials for smoking cessation, alcohol use disorder, and depression in cancer patients, spearheaded by Dr. Michael Bogenschutz and colleagues.

Quick Facts

Type: Other
HQ: United States
Website: Visit

Sponsored Trials

9

Not yet recruitingII

Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter

Start Date: January 15, 2026
Compounds: Psilocybin, Placebo

Psilocybin for Opioid Use Disorder (OUD)

Start Date: March 1, 2025
Compounds: Psilocybin

Not yet recruitingI

Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)

Start Date: January 1, 2025
Compounds: Psilocybin, Placebo

Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD

Start Date: July 1, 2024
Compounds: Psilocybin, Placebo

RecruitingII, III

Psilocybin Therapy in Advanced Cancer

Start Date: November 1, 2022
Compounds: Psilocybin, Placebo

The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious Professionals

Start Date: January 4, 2015
Compounds: Psilocybin

A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence

Start Date: June 1, 2014
Compounds: Psilocybin, Placebo

Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients

Start Date: January 12, 2013
Compounds: Ketamine, Placebo

Psilocybin Cancer Anxiety Study

Start Date: January 2, 2009
Compounds: Psilocybin, Placebo